184 related articles for article (PubMed ID: 7994783)
1. A randomized trial of early intravesical instillation of epirubicin in superficial bladder cancer. The Nagoya University Urological Oncology Group.
Okamura K; Murase T; Obata K; Ohshima S; Ono Y; Sakata T; Hasegawa Y; Shimoji T; Miyake K
Cancer Chemother Pharmacol; 1994; 35 Suppl():S31-5. PubMed ID: 7994783
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of prophylactic intravesical chemotherapy with epirubicin in the treatment of superficial bladder cancer. Tokyo Women's Medical College Bladder Cancer Collaborating Group.
Ryoji O; Toma H; Nakazawa H; Goya N; Okumura T; Sonoda T; Kihara T; Tanabe K; Onizuka S; Tomoe H
Cancer Chemother Pharmacol; 1994; 35 Suppl():S60-4. PubMed ID: 7994789
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of intravesical chemoprophylaxis of epirubicin after transurethral resection of bladder tumors. Tottori University Oncology Group.
Watanabe N; Miyagawa I; Higasibori Y; Nakahara T; Sumi F; Ishida G; Abe B; Inoue A; Hanamoto N
Cancer Chemother Pharmacol; 1994; 35 Suppl():S57-9. PubMed ID: 7994788
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial. Kobe University Urological Oncology Group.
Eto H; Oka Y; Ueno K; Nakamura I; Yoshimura K; Arakawa S; Kamidono S; Obe S; Ogawa T; Hamami G
Cancer Chemother Pharmacol; 1994; 35 Suppl():S46-51. PubMed ID: 7994786
[TBL] [Abstract][Full Text] [Related]
5. The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin for prophylaxis of recurrence of superficial bladder cancer: a preliminary report.
Uekado Y; Hirano A; Shinka T; Ohkawa T
Cancer Chemother Pharmacol; 1994; 35 Suppl():S65-8. PubMed ID: 7994790
[TBL] [Abstract][Full Text] [Related]
6. [Intravesical instillation of epirubicin in the prophylactic treatment of recurrent superficial bladder cancer].
Kobayashi M; Sugaya Y; Yuzawa M; Morita T; Kobayashi Y; Tokue A
Hinyokika Kiyo; 1998 Dec; 44(12):861-4. PubMed ID: 10028430
[TBL] [Abstract][Full Text] [Related]
7. Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: a prospective, randomized controlled study.
Saika T; Tsushima T; Nasu Y; Miyaji Y; Saegusa M; Takeda K; Kumon H
World J Urol; 2010 Aug; 28(4):413-8. PubMed ID: 20054553
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of prophylactic intravesical chemotherapy with 4'-epirubicin in recurrent superficial bladder cancer: comparison of 4'-epirubicin and adriamycin.
Shuin T; Kubota Y; Noguchi S; Hosaka M; Miura T; Kondo I; Fukushima S; Ishizuka E; Furuhata A; Moriyama M
Cancer Chemother Pharmacol; 1994; 35 Suppl():S52-6. PubMed ID: 7994787
[TBL] [Abstract][Full Text] [Related]
9. Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin is not indicated for superficial bladder cancer.
Tozawa K; Okamura T; Sasaki S; Kawai N; Ito Y; Hayashi Y; Kohri K
Urol Int; 2001; 67(4):289-92. PubMed ID: 11741130
[TBL] [Abstract][Full Text] [Related]
10. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
[TBL] [Abstract][Full Text] [Related]
11. Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery.
Chen J; Yao Z; Qiu S; Chen L; Wang Y; Yang J; Li J
Cardiovasc Intervent Radiol; 2013 Dec; 36(6):1521-1526. PubMed ID: 23511989
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
Koga H; Kuroiwa K; Yamaguchi A; Osada Y; Tsuneyoshi M; Naito S
J Urol; 2004 Jan; 171(1):153-7. PubMed ID: 14665865
[TBL] [Abstract][Full Text] [Related]
13. A randomized study of short-versus long-term intravesical epirubicin instillation for superficial bladder cancer. Nagoya University Urological Oncology Group.
Okamura K; Kinukawa T; Tsumura Y; Otani T; Itoh H; Kobayashi H; Matsuura O; Kobayashi M; Fukatsu T; Ohshima S
Eur Urol; 1998; 33(3):285-8; discussion 289. PubMed ID: 9555553
[TBL] [Abstract][Full Text] [Related]
14. Alpha 2-b interferon and farmarubicin in the prophylaxis of recurrence of superficial transitional cell carcinoma of the urinary bladder.
Cervenakov I; Szoldova K; Mardiak J; Chovan D; Mala M; Slavov D
Bratisl Lek Listy; 2000; 101(6):317-20. PubMed ID: 11039202
[TBL] [Abstract][Full Text] [Related]
15. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.
Ali-el-Dein B; el-Baz M; Aly AN; Shamaa S; Ashamallah A
J Urol; 1997 Jul; 158(1):68-73; discussion 73-4. PubMed ID: 9186325
[TBL] [Abstract][Full Text] [Related]
16. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder.
Oosterlinck W; Kurth KH; Schröder F; Bultinck J; Hammond B; Sylvester R
J Urol; 1993 Apr; 149(4):749-52. PubMed ID: 8455236
[TBL] [Abstract][Full Text] [Related]
17. Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer.
Melekos MD; Chionis HS; Paranychianakis GS; Dauaher HH
Cancer; 1993 Sep; 72(5):1749-55. PubMed ID: 8348504
[TBL] [Abstract][Full Text] [Related]
18. Significance of the preoperative intravesical instillation of doxorubicin and the oral administration of 5-fluorouracil in preventing recurrence after a transurethral resection of superficial bladder cancer. Kyushu University Urological Oncology Group.
Naito S; Iguchi A; Sagiyama K; Ariyoshi A; Osada Y; Omoto T; Kuriya N; Kumazawa J
Int J Urol; 1997 Jul; 4(4):352-7. PubMed ID: 9256323
[TBL] [Abstract][Full Text] [Related]
19. Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection.
Mitsumori K; Tsuchiya N; Habuchi T; Li Z; Akao T; Ohyama C; Sato K; Kato T
BJU Int; 2004 Aug; 94(3):317-21. PubMed ID: 15291859
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy with early intravesical instillation of adriamycin and long-term oral administration of 5-fluorouracil in superficial bladder cancer. The Kyushu University Urological Oncology Group.
Ueda T; Naito S; Iguchi A; Sagiyama K; Osada Y; Ariyoshi A; Omoto T; Kumazawa J
Cancer Chemother Pharmacol; 1992; 30 Suppl():S31-6. PubMed ID: 1394813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]